Zepbound (tirzepatide) - Eli Lilly
Novel Therapeutic Approaches to Treating Polysubstance Abuse: Alcohol and Nicotine Co-Use (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR195.03 / GG15; Pres time: Nov 16, 2026; 01:00 PM - 05:00 PM; Location: WCC Halls A-C; "Moreover, this model was designed so that rats could deliver these drugs via the most common human routes (alcohol liquid for oral consumption and nicotine vapor for inhalation) giving it considerable translational value...Here we show that the GLP-1 agonist tirzepatide decreases aspects of both alcohol and nicotine seeking in both males and females. Together, these studies point in several new directions for potential therapeutics for alcohol and nicotine co-use." 
CNS Disorders • TLR3
https://www.abstractsonline.com/pp8/#!/21503/presentation/24641
 
C. A. RANDALL1; P. A. RANDALL2
 
Sep 27, 2026
 
Prev Next